RIM
VRTX icon

Regent Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Regent Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-700
Closed -$203K – 194
2020
Q2 		$203K Buy
+700
New +$190K 0.07% 176
2020
Q1 		– Sell
-950
Closed -$208K – 207
2019
Q4 		$208K Buy
+950
New +$192K 0.06% 198

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Regent Investment Management's VRTX Position: Q3 2020 in Review

Regent Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 700 shares — an estimated $203K sold.

Regent Investment Management first reported a position in VRTX in Q4 2019 and held it in 2 quarters. The position peaked at $208K in Q4 2019. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Regent Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Regent Investment Management sold 700 Vertex Pharmaceuticals shares in Q3 2020, an estimated $203K.
  • Regent Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Regent Investment Management's Vertex Pharmaceuticals position peaked at $208K in Q4 2019.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Regent Investment Management's 13F filing for Q3 2020, filed 19 Oct 2020.